GlaxoSmithKline (GSK) have signed a worldwide non-exclusive agreement to license some of Vectura's dry powder drug formulation patents in relation to two late stage development compounds in GSK's respiratory ....
GenVec announces a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new ....
Janssen Pharmaceutica has licensed worldwide rights to Depomed 's Acuform gastric retentive drug delivery technology to be used for the non-exclusive development of a fixed dose combination formulation ....
Seattle Genetics announces that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech. Under the expanded agreement, Genentech will pay an upfront fee of US$12 million ....
PerkinElmer announces that it has acquired VisEn Medical. The acquisition enables PerkinElmer to enhance its cellular imaging business, by expanding the company's technologies and capabilities downstream ....
Agilent Technologies signs a memorandum of understanding (MoU) with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), an agency under the Ministry ....
The partners in a new publicly-funded European research project announce details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC (European ....
Pure Bioscience announces that based on encouraging preclinical data it has granted two product-specific licenses to pharmaceutical development partner FTA Bioscience for development of a silver dihydrogen ....
FivePrime Therapeutics announces that it has formed a focused strategic drug discovery alliance with GlaxoSmithKline (GSK). This collaboration gives GSK exclusive access to Five Prime's drug discovery ....
Actient announces it has completed a transaction to license and acquire six pharmaceutical products from UCB. The product set will form the basis of a commercial platform upon which Actient will continue ....